Ensysce Biosciences, INC

Ensysce Biosciences, Inc. announced the resignation of its Chief Operating Officer, Jeffrey Millard, effective July 10, 2026.

Ensysce Biosciences has received a deficiency notice from Nasdaq for failing to meet the minimum stockholders equity requirement of $2.5 million.

Ensysce Biosciences, Inc. announced the resignation of a Board of Directors member, effective April 1, 2026.

Ensysce Biosciences, Inc. filed a Certificate of Correction to amend a scrivener's error in its Series B Preferred Stock designation related to common stock conversion limits.

Ensysce Biosciences Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Ensysce Biosciences, Inc. stockholders approved the full issuance of shares and warrants, increased the share pool for its incentive plan, and re-elected two Class I Directors at its annual meeting.

Ensysce Biosciences reported a significant increase in net loss and cash burn for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Ensysce Biosciences, a clinical-stage biotech, reported significant operating losses in Q3 2025 and for the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Ensysce Biosciences reported a reduced net loss in Q2 2025, driven by increased grant funding and R&D activities, but faces substantial doubt about its ability to continue as a going concern without further capital.

Ensysce Biosciences' Q1 2025 shows increased grant revenue and reduced net loss compared to Q1 2024, but the company still faces substantial doubt about its ability to continue as a going concern.

Ensysce Biosciences saw a significant increase in federal grant revenue and completed multiple equity raises in Q3 2024, while research and development expenses decreased.

Ensysce Biosciences reported its financial results for the second quarter of 2024, highlighting ongoing research and development activities and the need for additional funding.

Ensysce Biosciences details its financial results for 2024 and provides an update on its clinical development programs focused on pain relief and abuse prevention.

Ensysce Biosciences, a clinical-stage pharmaceutical company, released its 2023 annual report, detailing financial performance and progress in its drug development programs.

Ensysce Biosciences, Inc. has filed definitive additional proxy soliciting materials with the SEC.

Ensysce Biosciences, Inc. calls for its Annual Meeting on December 23, 2025, to seek stockholder approval for a significant equity issuance to an institutional investor, an increase in its incentive plan share reserve, and director elections.

Ensysce Biosciences has issued a supplement to its proxy statement clarifying that brokers have discretionary voting authority on Proposals 2, 4, and 5 at the upcoming annual meeting.

Ensysce Biosciences, Inc. has filed a definitive proxy statement with the SEC.

Ensysce Biosciences is holding a virtual annual meeting on November 21, 2024, to vote on proposals including share issuance approval, a reverse stock split, director elections, and auditor ratification.

Ensysce Biosciences is registering for the potential issuance and resale of up to 7,455,627 shares of common stock underlying warrants held by selling securityholders.

Ensysce Biosciences is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.

Adage Capital Management and its principals have disclosed a 3.15% passive beneficial ownership stake in Ensysce Biosciences, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amendment to disclose a passive 3.7% beneficial ownership stake in Ensysce Biosciences, Inc.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 5.32% in Ensysce Biosciences, Inc.'s common stock.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, confirming their beneficial ownership of 5.3% of Ensysce Biosciences, Inc.'s common stock.

RA Capital Management, along with its affiliates, has reported a complete divestment of its beneficial ownership in Ensysce Biosciences, Inc., reducing its stake to 0% as of December 31, 2024.

Anson Funds Management LP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 2.1% in Ensysce Biosciences, Inc. as of December 31, 2024.